AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27764906 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 IV on D1 (D)
Number of subjects: 72
Study 27764906 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 60 mg/m2 IV plus cisplatin 60 mg/m² IV on D1 (DC)
Number of subjects: 72
Study 27764906 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 IV D1 plus oral S-1 30 mg/m2 twice a day on D1-14 (DS)
Number of subjects: 72
Study 27488051 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline and metformin therapy for 26 weeks
Number of subjects: 40
Study 27488051 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 40
Study 27488051 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline and metformin therapy
Number of subjects: 40
Study 25056431 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based shared-care software
Number of subjects: 30
Study 25056431 — intervention group
Group type: EXPERIMENTAL
Intervention: Software implementation and performance
Number of subjects: 30
Study 25056431 — intervention group
Group type: EXPERIMENTAL
Intervention: GP users' evaluation via questionnaire
Number of subjects: 30
Study 25056431 — intervention group
Group type: EXPERIMENTAL
Intervention: Software usage collected via GP questionnaire
Number of subjects: 30
Study 21555171 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucous tramadol 50mg (1mL of saline)
Number of subjects: 20
Study 21555171 — intervention group
Group type: COMPARATOR
Intervention: Submucous placebo (1mL of saline)
Number of subjects: 20
Study 19614635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.1 mmol/kg
Number of subjects: 50
Study 19614635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.3 mmol/kg
Number of subjects: 50
Study 19614635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.5 mmol/kg
Number of subjects: 50
Study 19614635 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 50
Study 19614635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17442681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 24
Study 17442681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) + Caffeine (130 mg)
Number of subjects: 24
Study 17442681 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (130 mg)
Number of subjects: 24
Study 17442681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15896835 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based expert systems intervention for smoking cessation
Number of subjects: 5407
Study 15896835 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based expert systems intervention for dietary improvement
Number of subjects: 5407
Study 15896835 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based expert systems intervention for sun exposure reduction
Number of subjects: 5407
Study 15896835 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based expert systems intervention for regular mammography adherence
Number of subjects: 5407
Study 11817529 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated (HC) VVBP equipment
Number of subjects: 20
Study 11817529 — intervention group
Group type: COMPARATOR
Intervention: Noncoated (NC) VVBP circuits
Number of subjects: 20
Study 9585294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (Xefo; administered i.v. via PCA for up to 24 h)
Number of subjects: 96
Study 9585294 — intervention group
Group type: COMPARATOR
Intervention: Morphine (administered i.v. via PCA for up to 24 h)
Number of subjects: 96
Study 7543580 — intervention group
Group type: EXPERIMENTAL
Intervention: Project CHILD program (Community Health Initiatives Against Learning Difficulties)
Number of subjects: 0
Study 7543580 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational and medical screenings
Number of subjects: 0
Study 7543580 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental empowerment initiatives
Number of subjects: 0
Study 7543580 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based and comprehensive child health care
Number of subjects: 0
Study 1639833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast lifting condition
Number of subjects: 5
Study 1639833 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated lifting condition
Number of subjects: 5
Study 1639833 — intervention group
Group type: COMPARATOR
Intervention: Slow lifting condition
Number of subjects: 5
Study 1639833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast lowering condition
Number of subjects: 5
Study 1639833 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow lowering condition
Number of subjects: 5
Study 1639833 — intervention group
Group type: COMPARATOR
Intervention: Maximal values from isokinetic dynamometry
Number of subjects: 5
Study 6383447 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam plus pethidine, reversed with naloxone
Number of subjects: 100
Study 6383447 — intervention group
Group type: COMPARATOR
Intervention: Diazepam alone
Number of subjects: 100
Study 30274699 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-induced thermo-chemotherapy effect (RITE) with 40mg mitomycin-C at 42±2°C for 60 minutes
Number of subjects: 104
Study 30274699 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-induced thermo-chemotherapy effect (RITE)
Number of subjects: 104
Study 30274699 — intervention group
Group type: COMPARATOR
Intervention: Control (institutional standard second-line therapy)
Number of subjects: 104
Study 29173218 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategy implementation intervention
Number of subjects: 45
Study 29173218 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 45
Study 26970266 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (150-200 mg/day)
Number of subjects: 867
Study 24887579 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Heart Failure Model (SHFM) score increase by 1 unit
Number of subjects: 2331
Study 22976237 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a computerized language lateralization index (CLI)
Number of subjects: 22
Study 22976237 — intervention group
Group type: COMPARATOR
Intervention: No use of a computerized language lateralization index (CLI)
Number of subjects: 22
Study 20571015 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B12
Number of subjects: 12064
Study 20571015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12064
Study 18465241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting 500 ml of polyethylene glycol (PEG) starting 30 min after swallowing the capsule
Number of subjects: 59
Study 18465241 — intervention group
Group type: COMPARATOR
Intervention: No preparation (control group A)
Number of subjects: 59
Study 16371776 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A 0.05% (tCsA)
Number of subjects: 33
Study 16371776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Refresh Plus preservative-free artificial tears)
Number of subjects: 33
Study 14645769 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone disease management (TDM) program
Number of subjects: 97
Study 14645769 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study 10999974 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate increases in alcohol consumption (>1 to <6 drinks per week) among men initially consuming 1 drink per week or less (n=7360)
Number of subjects: 18455
Study 10999974 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate increases in alcohol consumption among men initially consuming greater than 1 to 6 drinks per week (n=6612)
Number of subjects: 18455
Study 10999974 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased alcohol intake among men initially consuming 1 drink per day or more (n=4483)
Number of subjects: 18455
Study 9004052 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (mean daily dosage at 6 weeks 169 +/- 42 mg)
Number of subjects: 40
Study 9004052 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (mean daily dosage at 6 weeks 37 +/- 18 mg)
Number of subjects: 40
Study 8285374 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg (plain tablet)
Number of subjects: 8
Study 8285374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 3100877 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone nasal solution
Number of subjects: 120
Study 3100877 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 120
Study 3100877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn
Number of subjects: 120
Study 3100877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3100877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (Beclomethasone and Flunisolide)
Number of subjects: 120
Study 30636826 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg melatonin tablets 45 min before sleep for 3 days after surgery
Number of subjects: 100
Study 30636826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26910256 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 581
Study 26910256 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 581
Study 24854816 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertent exposure to media body ideal images
Number of subjects: 174
Study 24854816 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadvertent exposure to media body ideal images
Number of subjects: 174
Study 24854816 — intervention group
Group type: COMPARATOR
Intervention: Control images
Number of subjects: 174
Study 22697189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole-IM-depot (400 mg every 4 weeks, with coadministration of oral aripiprazole for the first 2 weeks)
Number of subjects: 403
Study 22697189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 20840173 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling
Number of subjects: 403
Study 20840173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 403
Study 20840173 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 403
Study 17324600 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.058 IU/kg/day for 6 days
Number of subjects: 48
Study 17324600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 16246996 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 255
Study 16246996 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (75 mg once daily)
Number of subjects: 255
Study 16246996 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR
Number of subjects: 255
Study 16246996 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 255
Study 16246996 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (placebo)
Number of subjects: 255
Study 11893367 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive drugs (e.g., alendronate)
Number of subjects: 12
Study 11893367 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (in the Fracture Intervention Trial)
Number of subjects: 12
Study 11893367 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive treatments (general)
Number of subjects: 12
Study 8154632 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol via metered dose inhaler (MDI)
Number of subjects: 18
Study 8154632 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol via AeroChamber
Number of subjects: 18
Study 8154632 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol via OptiHaler
Number of subjects: 18
Study 8154632 — intervention group
Group type: COMPARATOR
Intervention: Placebo via metered dose inhaler (MDI)
Number of subjects: 18
Study 8154632 — intervention group
Group type: COMPARATOR
Intervention: Placebo via AeroChamber
Number of subjects: 18
Study 8154632 — intervention group
Group type: COMPARATOR
Intervention: Placebo via OptiHaler
Number of subjects: 18
Study 8154632 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices (MDI, AeroChamber, OptiHaler)
Number of subjects: 18
Study 8154632 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 18
Study 3341973 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mW laser power directed at anterior trabecular meshwork
Number of subjects: 119
Study 3341973 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mW laser power directed at posterior trabecular meshwork
Number of subjects: 119
Study 3341973 — intervention group
Group type: COMPARATOR
Intervention: ALT procedure
Number of subjects: 119
Study 31975494 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 31
Study 31975494 — intervention group
Group type: COMPARATOR
Intervention: Sham pacing
Number of subjects: 31
Study 31564432 — intervention group
Group type: EXPERIMENTAL
Intervention: ultra‐rapid whole‐genome sequencing (urWGS)
Number of subjects: 213
Study 31564432 — intervention group
Group type: COMPARATOR
Intervention: rapid whole‐exome sequencing (rWES)
Number of subjects: 213
Study 31564432 — intervention group
Group type: COMPARATOR
Intervention: rapid whole‐genome sequencing (rWGS)
Number of subjects: 213
Study 31564432 — intervention group
Group type: EXPERIMENTAL
Intervention: reflexing to trio after negative proband analysis
Number of subjects: 213
Study 28152016 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to digital marketing contents of energy drinks (via websites and social media for 8 minutes)
Number of subjects: 60
Study 28152016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to digital marketing)
Number of subjects: 60
Study 25119144 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-color graphic warning labels
Number of subjects: 0
Study 25119144 — intervention group
Group type: EXPERIMENTAL
Intervention: Black-and-white graphic warning labels
Number of subjects: 0
Study 25119144 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning text (no graphic image)
Number of subjects: 0
Study 25119144 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon General's warning labels
Number of subjects: 0
Study 25119144 — intervention group
Group type: EXPERIMENTAL
Intervention: No warning
Number of subjects: 0
Study 24063778 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-site abdominal hot-stone stimulation (umbilicus, superior-umbilicus, inferior-umbilicus) for 9 min
Number of subjects: 25
Study 24063778 — intervention group
Group type: COMPARATOR
Intervention: One-site abdominal hot-stone stimulation (umbilicus) for 9 min
Number of subjects: 25
Study 22256669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical/horizontal combination grab bar configuration
Number of subjects: 80
Study 22256669 — intervention group
Group type: EXPERIMENTAL
Intervention: L-shaped bar configuration
Number of subjects: 80
Study 22256669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical/angled combination grab bar configuration
Number of subjects: 80
Study 22256669 — intervention group
Group type: COMPARATOR
Intervention: No bars (control group)
Number of subjects: 80
Study 19636001 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan/fluorouracil, fluorouracil/oxaliplatin, or irinotecan/oxaliplatin
Number of subjects: 1412
Study 16451762 — intervention group
Group type: EXPERIMENTAL
Intervention: Padding in dental mirror handle design
Number of subjects: 19
Study 16451762 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of diameter and weight in dental mirror handle design
Number of subjects: 19
Study 16451762 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight in dental mirror handle design
Number of subjects: 19
Study 15247140 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 136
Study 11377155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope (BL)
Number of subjects: 50
Study 11377155 — intervention group
Group type: COMPARATOR
Intervention: Flexible fiberoptic bronchoscope (FFB)
Number of subjects: 50
Study 11377155 — intervention group
Group type: COMPARATOR
Intervention: FFB with no cricoid pressure
Number of subjects: 50
Study 9225183 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngotracheoplasty
Number of subjects: 10
Study 9225183 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 8495830 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation
Number of subjects: 50
Study 8495830 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 50
Study 2468875 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 22
Study 2468875 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 22
Study 31138156 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant hospitals
Number of subjects: 7803
Study 31138156 — intervention group
Group type: COMPARATOR
Intervention: Non-transplant hospitals
Number of subjects: 7803
Study 31138156 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant and non-transplant hospitals
Number of subjects: 7803
Study 28665542 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (N=570)
Number of subjects: 1012
Study 28665542 — intervention group
Group type: COMPARATOR
Intervention: Standard care (N=442)
Number of subjects: 1012
Study 28665542 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (N=341)
Number of subjects: 1012
Study 28665542 — intervention group
Group type: COMPARATOR
Intervention: Standard care (N=234)
Number of subjects: 1012
Study 25512220 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlite continuous glucose monitoring sensor system
Number of subjects: 0
Study 24305424 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A and hyaluronic acid filler
Number of subjects: 20
Study 24305424 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A alone
Number of subjects: 20
Study 21429720 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-g soy protein and 100-mg isoflavone
Number of subjects: 180
Study 21429720 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-g milk protein and 100-mg isoflavone
Number of subjects: 180
Study 21429720 — intervention group
Group type: COMPARATOR
Intervention: 15-g milk protein (placebo group)
Number of subjects: 180
Study 21429720 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy group
Number of subjects: 180
Study 21429720 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso group
Number of subjects: 180
Study 21429720 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 180
Study 18462730 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol combined with folic acid (Inofolic) 2 g twice a day
Number of subjects: 60
Study 18462730 — intervention group
Group type: COMPARATOR
Intervention: Folic acid alone
Number of subjects: 60
Study 17552953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day ciprofloxacin XR 1000 mg
Number of subjects: 497
Study 17552953 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day ciprofloxacin XR 1000 mg
Number of subjects: 497
Study 15578804 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid aerosol pH 5.0
Number of subjects: 79
Study 15578804 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid aerosol pH 3.0
Number of subjects: 79
Study 15578804 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid aerosol pH 2.0
Number of subjects: 79
Study 15578804 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid aerosol (all pH levels)
Number of subjects: 79
Study 15578804 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol pretreatment
Number of subjects: 79
Study 11738848 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 21
Study 11738848 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 10193275 — intervention group
Group type: EXPERIMENTAL
Intervention: Air tonometry (raPCO2)
Number of subjects: 19
Study 10193275 — intervention group
Group type: COMPARATOR
Intervention: Saline tonometry (rsPCO2)
Number of subjects: 19
Study 10193275 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of air and saline tonometry
Number of subjects: 19
Study 7835330 — intervention group
Group type: EXPERIMENTAL
Intervention: FE-27 (27 mg iron x day‐1)
Number of subjects: 64
Study 7835330 — intervention group
Group type: EXPERIMENTAL
Intervention: FE-9 (9 mg iron x day‐1)
Number of subjects: 64
Study 7835330 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FE-9 and FE-27
Number of subjects: 64
Study 7835330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 3284974 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and Prednisone (MP)
Number of subjects: 410
Study 3284974 — intervention group
Group type: COMPARATOR
Intervention: Semustine, Cyclophosphamide, and Prednisone (MeCP)
Number of subjects: 410
Study 3284974 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan, Prednisone, Cyclophosphamide, Semustine, and Vincristine (MPCCV)
Number of subjects: 410
Study 31841023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 8 weeks
Number of subjects: 130
Study 31841023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) for 8 weeks
Number of subjects: 130
Study 31841023 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) and Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130
Study 31841023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130
Study 28541646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)
Number of subjects: 58
Study 28541646 — intervention group
Group type: COMPARATOR
Intervention: Geriatric case management (CM)
Number of subjects: 58
Study 28254462 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3652 25 mg twice daily
Number of subjects: 239
Study 28254462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239